The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.
In exchange, Editas has the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.
The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
The wide-ranging discussion with witnesses from Stanford, Johns Hopkins, and Editas Medicine touched on recent advances in research and questions of safety.
In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.
The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.
The firm plans to sell 4 million shares of common stock to support preclinical studies and clinical trials of CRISPR-based human therapies, among other uses.
Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.